Best Warren Buffett Stocks To Watch Right Now

Berkshire's MidAmerican Energy is heavily invested in alternative fuels. Will BNSF follow suit with LNG? Source: BNSF.

Last year,�Berkshire Hathaway�subsidiary BNSF Railway announced that it would begin testing liquefied natural gas-powered locomotives toward the end of 2013. BNSF CEO Matt Rose had this to say:

The use of liquefied natural gas as an alternative fuel is a potential transformational change for our railroad and for our industry ... While there are daunting technical and regulatory challenges still to be faced, this pilot project is an important first step that will allow BNSF to evaluate the technical and economic viability of the use of liquefied natural gas in through-freight service, potentially reducing fuel costs and greenhouse gas emissions, thereby providing environmental and energy security benefits to our nation.

Consider, on top of that, that Berkshire has more than $6 billion invested in companies heavily involved in natural gas production and distribution, and�it's not a stretch to see Warren Buffett having reached the conclusion that domestic production of oil and natural gas will continue to be strong, and that natural gas will keep gaining traction as a transportation fuel. How big is this to Berkshire?�

Top 5 China Stocks To Watch For 2015: Nektar Therapeutics(NKTR)

Nektar Therapeutics, a clinical-stage biopharmaceutical company, engages in developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms. The company?s product pipeline consists of drug candidates across various therapeutic areas, including oncology, pain, anti-infectives, anti-viral, and immunology. Its research and development activities involve small molecule drugs, peptides, and other potential biologic drug candidates. The company?s proprietary drug candidates in clinical development comprise NKTR-118, a peripheral opioid antagonist, which has completed Phase II clinical trail for the treatment of opioid-induced constipation; BAY41-6551 that has completed Phase II clinical trail to treat gram-negative pneumonias; NKTR-102, a topoisomerase I inhibitor-polymer conjugate, which is in Phase II clinical trail for multiple cancer indications, including breast, ovarian, and colorectal; and NKTR-105 that is in Phase I clinica l trail to treat solid tumors. Its preclinical products consists of NKTR-119 (Opioid/NKTR-118 combinations) for the treatment of pain; NKTR-181 (abuse deterrent, tamper-resistant opioid) to treat pain; NKTR-194 (non-scheduled opioid) for the treatment of mild to moderate pain; NKTR-171 (tricyclic antidepressant) to treat neuropathic pain; and NKTR-140 (protease inhibitor candidate) to treat HIV. The company has collaboration with Bayer Healthcare LLC to develop BAY41-6551 (NKTR-061, Amikacin Inhale), which is an inhaled solution of amikacin, an aminoglycoside antibiotic; and a license agreement with AstraZeneca AB for the development and commercialization of Oral NKTR-118 and NKTR-119. In addition, Nektar Therapeutics has various license, manufacturing, and supply agreements for its technology with biotechnology and pharmaceutical companies, such as Affymax, Amgen, Baxter, Roche, Merck, Pfizer, and UCB Pharma. The company was founded in 1990 and is headquartered in San Franc isco, California.

Advisors' Opinion:

• [By Sean Williams]

  Nektar Therapeutics (NASDAQ: NKTR  ) delivered a double-digit gain for shareholders this week after reporting positive top-line data for NKTR-181, its oral chronic pain-treatment drug. NKTR-181 is an opioid-based compound that's designed to enter the brain slower than traditional opiates like oxycodone without sacrificing effectiveness and ultimately reducing addiction-like qualities to the medication. In trials, the data demonstrated that NKTR-181 had a statistically significant lower "drug liking" and "feeling high" score than oxycodone. While I'd certainly exercise caution in getting too excited, as the Food and Drug Administration is very harsh with regard to its regulation of opioid-based drugs, it's nonetheless good news for Nektar.

• [By Sean Williams]

  Levadex's approval or rejection could also mean a good or bad day for Nektar Therapeutics (NASDAQ: NKTR  ) , which looks to gain from royalty rights based on its contributions to Levadex's development. While impossible to predict, I'm going to go out on a limb and project an approval for Allergan.

• [By Keith Speights]

  How sweet it is
  Nektar Therapeutics (NASDAQ: NKTR  ) shareholders saw sweet gains this week. The stock climbed 18% on positive clinical study results.

Best Warren Buffett Stocks To Watch Right Now: Student Transportation Inc (STB)

Student Transportation Inc. (STI) is a provider of school bus transportation services in North America, conducting operations through wholly owned operating subsidiaries. The Company operates in two segments: a transportation segment and an oil and gas segment. The transportation segment provides school bus and management services to public and private schools in North America. The oil and gas segment represents its investments as a non-operator in oil and gas interests. During the fiscal year ended June 30, 2012 (fiscal 2012), it acquired certain assets of Schumacher Bus Lines; certain assets and contracts of S&K Transportation Inc.; A&B Bus, Co.; School Transportation Services, LLC.; Dairyland Bus, Inc., Dairyland-Hamilton, Inc., Lakeland Area Bus Service, Inc. and Lakeside Buses of Wisconsin, Inc., and certain assets and contracts of Safe Start Transportation of New Jersey, LLC. On May 24, 2012, the Company acquired certain assets and contracts of National Express Corporation. Advisors' Opinion:

• [By Charles Sizemore]

  Finally, for an off-the-wall pick, consider picking up shares of Student Transportation (STB), North America�� third-largest operator of school buses.� Student Transportation doesn’t just operate more than 10,000 school buses and transport more than a million students daily across the United States and Canada. It’s a monthly dividend stock with a solid yield.

Best Warren Buffett Stocks To Watch Right Now: TE Connectivity Ltd.(TEL)

TE Connectivity Ltd. provides engineered electronic components, network solutions, specialty products, and subsea telecommunication systems. Its Electronic Components segment supplies passive electronic components, which include connectors and interconnect systems, relays, switches, sensors, and wire and cable to original equipment manufacturers and their contract manufacturers in the automotive, data communications, industrial, appliance, computer, and consumer devices markets. The company?s Network Solutions segment supplies infrastructure components and systems for telecommunications and energy markets. This segment provides components comprising connectors, above- and below-ground enclosures, heat shrink tubing, cable accessories, surge arrestors, fiber optic cabling, copper cabling, and racks for copper and fiber networks; electronic systems for test access and intelligent cross-connect applications; and integrated cabling solutions for cabling and building management . This segment also sells insulators, power measurement products, CATV accessories, network interface devices, raceway systems, and duct accessories. Its Specialty Products segment offers engineered custom solutions, components, and connectors for electronic systems, subsystems, and devices in the aerospace, defense, and marine; touch systems; medical; and circuit protection markets. The company?s Subsea Communications segment designs, builds, maintains, and tests undersea fiber optic networks for the telecommunications, and oil and gas markets. It sells its products in the Americas, Europe/the Middle East/Africa, and the Asia-Pacific. The company was formerly known as Tyco Electronics Ltd. and changed its name to TE Connectivity Ltd. on March 10, 2011. TE Connectivity Ltd. was founded in 1941 and is based in Schaffhausen, Switzerland.

Advisors' Opinion:

• [By Garrett Cook]

  Measurement Specialties (NASDAQ: MEAS) shares shot up 10.46 percent to $86.16 after the company agreed to be acquired by TE Connectivity (NYSE: TEL) for $86 cash per share.

• [By Monica Wolfe]

  TE Connectivity (TEL)

  Bill Nygren�� fourth largest position is in TE Connectivity where he maintains 4,686,000 shares of the company�� stock. His holdings in TE Connectivity make up for 2.5% of his total assets managed and 1.13% of the company�� shares outstanding.

• [By alicet236]

  TE Connectivity Ltd. (TEL): Chairman and CEO Thomas J. Lynch Sold 49,021 Shares

  Chairman and CEO of TE Connectivity Ltd. (TEL) Thomas J. Lynch sold 49,021 shares on 10/07/2013 at an average price of $51.6. Te Connectivity Ltd. has a market cap of $21.44 billion; its shares were traded at around $51.85 with a P/E ratio of 17.20 and P/S ratio of 1.70. The dividend yield of TE Connectivity Ltd. stocks is 1.80%.

Best Warren Buffett Stocks To Watch Right Now: EDAP TMS S.A.(EDAP)

EDAP TMS S.A., through its subsidiaries, engages in the development, manufacture, and marketing of minimally invasive medical devices primarily for urological diseases. The company operates in two divisions, High Intensity Focused Ultrasound (HIFU), and Urology Devices and Services (UDS). The HIFU division involves in the development, manufacture, and marketing of medical devices based on HIFU technology for the minimally invasive destruction of various types of localized tumors. This division offers Ablatherm, a HIFU-based ultrasound guided device for the treatment of organ-confined prostate cancer. Its HIFU technology allows the surgeon to destroy a defined area of diseased tissue without damaging surrounding tissue and organs. This division also engages in the leasing of equipment, as well as the sale of disposables, spare parts, and maintenance services. This division markets and sells its products through its direct marketing and sales organization, as well as through third-party distributors and agents. The UDS division engages in the development, manufacture, marketing, and servicing of medical devices for the minimally invasive diagnosis or treatment of urological disorders, primarily urinary stones and other clinical indications. This division provides lithotripters for the treatment of urinary tract stones by means of ESWL technology. This division manufactures three models of lithotripters: the Sonolith Praktis, the Sonolith i-move, and the Sonolith i-sys. This division also involves in the leasing of lithotripters, as well as the sale of disposables, spare parts, and maintenance services. This division markets and sells its products through its direct sales and service platform, as well as through agents and third-party distributors. The company?s customers include public and private hospitals, urology clinics, and research institutions worldwide. EDAP TMS S.A. was founded in 1979 and is based in Vaulx-en-Velin, France.

Advisors' Opinion:

• [By Bryan Murphy]

  Last week, yours truly posed the unpopular (though largely ignored) premise that EDAP TMS S.A. (NASDAQ:EDAP) was poised to tumble. It wasn't anything personal, nor was it a judgment call on the merits of the company. It was simply a trading-based call, observing how the rally EDAP was enjoying at the time appeared to be running out of gas, and there was no floor to halt any pullback.